COMMUNIQUÉS West-GlobeNewswire
-
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
12/06/2024 - 22:05 -
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/06/2024 - 22:05 -
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
12/06/2024 - 22:05 -
NANOBIOTIX ORGANISE UNE DISCUSSION VIRTUELLE ENTRE EXPERTS SUR LE POTENTIEL DE NBTXR3 EN IMMUNOTHÉRAPIE DANS LE CANCER DE LA TÊTE ET DU COU ET D’AUTRES INDICATIONS LE 18 JUIN 2024
12/06/2024 - 22:15 -
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
12/06/2024 - 22:15 -
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
12/06/2024 - 22:15 -
Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications
12/06/2024 - 22:30 -
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
12/06/2024 - 22:30 -
Dentsply Sirona Provides Update on June Investor Conference Participation
12/06/2024 - 22:55 -
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
11/06/2024 - 14:00 -
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
11/06/2024 - 14:00 -
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
11/06/2024 - 14:10 -
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman
11/06/2024 - 14:15 -
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
11/06/2024 - 14:20 -
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301
11/06/2024 - 14:30 -
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
11/06/2024 - 14:30 -
SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
11/06/2024 - 14:30 -
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
11/06/2024 - 14:30 -
Sofwave Medical Receives Marketing Clearance in Canada for Pure Impact™ Strength and Muscle Toning Device
11/06/2024 - 14:33
Pages